Cargando…

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen

Prostate-specific membrane antigen (PSMA) theranostics have been introduced with (68)Ga and (177)Lu, the most used radionuclides. However, (188)Re is a well-known generator-based therapeutic nuclide that completes a theranostic tandem with (99m)Tc and may offer an interesting alternative to the curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardinale, Jens, Giesel, Frederik L., Wensky, Christina, Rathke, Hendrik G., Haberkorn, Uwe, Kratochwil, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2023
Materias:	Basic Science Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315696/ https://www.ncbi.nlm.nih.gov/pubmed/36759199 http://dx.doi.org/10.2967/jnumed.122.264944

Ejemplares similares

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients
por: Will, Leon, et al.
Publicado: (2017)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

Comparing (99m)Tc-PSMA to (99m)Tc-MDP in Prostate Cancer Staging of the Skeletal System
por: Kabunda, Joseph, et al.
Publicado: (2021)

Development of in-House Synthesis and Quality Control of [(99m)Tc]Tc-PSMA-I&S
por: Plhak, Elisabeth, et al.
Publicado: (2023)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

Targeting of activated fibroblasts for imaging and therapy
por: Lindner, Thomas, et al.
Publicado: (2019)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

[(99cm)Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center
por: Werner, P., et al.
Publicado: (2020)

[(99m)Tc]Tc-PSMA-T4—Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic
por: Maurin, Michał, et al.
Publicado: (2022)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Evaluation of Radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer
por: Zhang, Jianping, et al.
Publicado: (2020)

Preparation and Biological Evaluation of [(99m)Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer
por: Xiao, Di, et al.
Publicado: (2020)

A Review on the Current State and Future Perspectives of [(99m)Tc]Tc-Housed PSMA-i in Prostate Cancer
por: Brunello, Sara, et al.
Publicado: (2022)

[(18)F]PSMA-1007 PET is comparable to [(99m)Tc]Tc-DMSA SPECT for renal cortical imaging
por: Valind, Kristian, et al.
Publicado: (2023)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

(99m)Tc-Hydroxydiphosphonate quantification of extracellular matrix mineralization in 3D human mesenchymal stem cell cultures
por: Grossner, Tobias L., et al.
Publicado: (2019)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Fusion-Based Neutron Generator Production of Tc-99m and Tc-101: A Prospective Avenue to Technetium Theranostics
por: Mausolf, Edward J., et al.
Publicado: (2021)

Initial Experience of Clinical Use of [(99m)Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
por: Ćwikła, Jarosław B., et al.
Publicado: (2021)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging
por: Kessel, Katharina, et al.
Publicado: (2021)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

(18)F-labeled tracers targeting fibroblast activation protein
por: Lindner, Thomas, et al.
Publicado: (2021)

Tc-99m-PSMA-SPECT/CT Is Superior to Tc-99m-MDP-SPECT/CT in the Staging of Prostatic Cancer with Osseous Metastases after External Beam Radiotherapy
por: Liepe, Knut, et al.
Publicado: (2022)

Effects of Different Basal Cell Culture Media upon the Osteogenic Response of hMSCs Evaluated by (99m)Tc-HDP Labeling
por: Grossner, Tobias, et al.
Publicado: (2022)

Evaluation of the Impact of Different Pain Medication and Proton Pump Inhibitors on the Osteogenic Differentiation Potential of hMSCs Using (99m)Tc-HDP Labelling
por: Grossner, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mne1ga3rihoqjk6e59ui98i0qc